The company reveals its anti-GPRC5D T-cell engager.
ApexOnco Front Page
Recent articles
The company admits defeat with zelenectide.
Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.
HanchorBio’s HCB301 is among the latest industry projects beginning first-in-human trials.
Two years after being snubbed by GSK, Ideaya shows the promise of MAT2A inhibition.
The implosion of Skyscraper-06 has a direct impact on at least two other TIGIT players.
The group abandons plans in lung cancer with Met exon 14 skipping, to focus on Met amplifications.
Skyscraper-06 blows up spectacularly, and that’s bad news for Skyscraper-01.